Almost 5 million individuals in the United States have chronic heart failure (HF), which is
increasing in prevalence. Angiotensin‐converting enzyme (ACE) inhibitors are standard …

Multiple trials over the past several years have examined indications for angiotensin
receptor blockers (ARBs) in the treatment of left ventricular dysfunction, both acutely after …

Angiotensin-converting enzyme inhibitors (ACE-inhibitors) are first-line treatment for chronic
heart failure (CHF) with a low left ventricular ejection fraction because they improve …

The benefits of angiotensin-converting enzyme (ACE) inhibitors for the treatment of
congestive heart failure (CHF) are well-established. A newer class of medications …

More than 5 million Americans have congestive heart failure (CHF), and the lifetime
incidence of this disorder is now approximately 20%. Angiotensinconverting enzyme (ACE) …

Heart failure treatment centers on antagonism of the renin‐angiotensin‐aldosterone system
and adrenergic nervous system. Angiotensin‐converting enzyme (ACE) inhibitors have …

Background Heart failure (HF) is a major cause of morbidity and mortality in the United
States. The renin-angiotensin system (RAS) plays a major role in its pathophysiology, and …

The role of angiotensin receptor blockers (ARBs) in patients with left ventricular dysfunction
has changed after the VALIANT and CHARM trials. CHARM proved that candesartan is a …

Chronic heart failure is one of the most seri-ous cardiac problems encountered in clinical
practice. Modulation of the renin angiotensin system is a key element in the treatment of this …

In clinical heart failure (HF) the renin–angiotensin–aldosterone system is an important
component of neurohormonal activation. Angiotensin-converting enzyme inhibitors have …